José
Alcamí Pertejo
Publicaciones en las que colabora con José Alcamí Pertejo (47)
2023
-
Longer intervals between SARS-CoV-2 infection and mRNA-1273 doses improve the neutralization of different variants of concern
Journal of medical virology, Vol. 95, Núm. 3, pp. e28679
-
Persistent Immunity against SARS-CoV-2 in Individuals with Oncohematological Diseases Who Underwent Autologous or Allogeneic Stem Cell Transplantation after Vaccination
Cancers, Vol. 15, Núm. 8
2022
-
Early Cellular and Humoral Responses Developed in Oncohematological Patients after Vaccination with One Dose against COVID-19
Journal of Clinical Medicine, Vol. 11, Núm. 10
-
Strong Cellular Immune Response, but Not Humoral, against SARS-CoV-2 in Oncohematological Patients with Autologous Stem Cell Transplantation after Natural Infection
Journal of Clinical Medicine, Vol. 11, Núm. 8
-
Strong Humoral but Not Cellular Immune Responses against SARS-CoV-2 in Individuals with Oncohematological Disease Who Were Treated with Rituximab before Receiving a Vaccine Booster
Cancers, Vol. 14, Núm. 22
-
Transcriptomic Evidence of the Immune Response Activation in Individuals With Limb Girdle Muscular Dystrophy Dominant 2 (LGMDD2) Contributes to Resistance to HIV-1 Infection
Frontiers in Cell and Developmental Biology, Vol. 10
2021
-
A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia
Journal of Clinical Investigation, Vol. 131, Núm. 20
-
Identification of immunological parameters as predictive biomarkers of relapse in patients with chronic myeloid leukemia on treatment-free remission
Journal of Clinical Medicine, Vol. 10, Núm. 1, pp. 1-21
-
Impaired Antibody-Dependent Cellular Cytotoxicity in a Spanish Cohort of Patients With COVID-19 Admitted to the ICU
Frontiers in Immunology, Vol. 12
-
Impaired Cytotoxic Response in PBMCs From Patients With COVID-19 Admitted to the ICU: Biomarkers to Predict Disease Severity
Frontiers in Immunology, Vol. 12
-
Pharmacologic control of homeostatic and antigen-driven proliferation to target HIV-1 persistence
Biochemical Pharmacology, Vol. 194
-
Provirus reactivation is impaired in HIV-1 infected individuals on treatment with dasatinib and antiretroviral therapy
Biochemical Pharmacology, Vol. 192
2020
-
Cytotoxic cell populations developed during treatment with tyrosine kinase inhibitors protect autologous CD4+ T cells from HIV-1 infection
Biochemical Pharmacology, Vol. 182
-
Dasatinib protects humanized mice from acute HIV-1 infection
Biochemical Pharmacology, Vol. 174
2019
-
HCV-coinfection is related to an increased HIV-1 reservoir size in cART-treated HIV patients: a cross-sectional study
Scientific Reports, Vol. 9, Núm. 1
-
HIV Research for Prevention 2018: From Research to Impact Conference Summary and Highlights
AIDS Research and Human Retroviruses, Vol. 35, Núm. 7, pp. 598-607
-
The mutation of Transportin 3 gene that causes limb girdle muscular dystrophy 1F induces protection against HIV-1 infection
PLoS Pathogens, Vol. 15, Núm. 8
-
Tyrosine Kinase Inhibition: a New Perspective in the Fight against HIV
Current HIV/AIDS Reports, Vol. 16, Núm. 5, pp. 414-422
2018
-
Evaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors
Biochemical Pharmacology, Vol. 156, pp. 248-264
-
Factors leading to the loss of natural elite control of HIV-1 infection
Journal of Virology, Vol. 92, Núm. 5